The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1551
Firvanq - Vancomycin Oral Solution
The full article is available to subscribers Subscriber Login   

The FDA has approved vancomycin oral solution (Firvanq – Cutis Pharma) for treatment of Clostridium difficile-associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (MRSA).

ORAL VANCOMYCIN — Firvanq is the only FDA-approved vancomycin oral solution available in the US; it has replaced a vancomycin compounding kit (FIRST Kit-Vancomycin) marketed by the same manufacturer. An oral capsule formulation (Vancocin, and generics) is also available for the same indications.

The IV formulation of vancomycin has been used for many years to compound a solution for oral administration that costs much less than the oral capsules.1 Now that Firvanq is FDA-approved, compounding of vancomycin oral solution is no longer allowed, except in some rare situations (e.g., allergy ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Firvanq - Vancomycin Oral Solution
Article code: 1551d
 Electronic, downloadable article - $35
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian